Reports by Industry
Reports by Company
- Company Analysis(173)
- Company Profile(60)
Fast Developing mAb Market Poised to Hit 13.35% Growth
Jul 16, 2008
A new research report, “Global Protein Therapeutics Market Analysis”, by RNCOS reveals that the monoclonal antibodies (mAb) market is expected to grow at a CAGR of 13.35% through 2011.
As per the report, mAbs have shorter clinical trial period and faster development timeline in comparison to other drugs that ensures high success rate in development and launching of a mAb on the market. In 2006, about 17 therapeutic mAbs were available in the US market with over 40 new mAb-based therapies in Phase II or Phase III, or earlier stages of clinical development. On the basis of past approval rates, it is expected that 11 mAb products, currently in the pipeline, will be approved by the US Food and Drug Administration. Thus, the number of mAbs will be double the number of present mAbs and this will also lead to a radical rise in revenue generation.
The report identifies the rising number of AIIDS and cancer patients as a major future driver for mAb market. The gradually ageing populations in developed as well as developing countries are leading to a rise in the number of new cancer cases, which are expected to rise from 10 Million in 2000 to 15 Million in 2020. Also, the ability to prevent spreading of disease-inducing target cells without damaging healthy cells in the adjacent tissues distinguishes mAbs from other therapies and acts as a key driver for the market. mAb drugs attack specific antigens within cells, tissues and organs without any off-target effects, and thereby have minimum side effects. Thus, due to this feature, mAbs are commercially feasible and successfully used in clinical applications.
The RNCOS research report forecasts that AIIDS (Immune and inflammatory Disorders) and Oncology treatments, at 37% and 47% respectively, will account for the maximum share in the mAb market by 2011.
“Global Protein Therapeutics Market Analysis” provides extensive research and objective analysis on the global protein therapeutics industry. It provides detailed overview of various protein therapeutics used for disease prevention, drivers, market size, key geographical markets, major areas of application, opportunities and challenges critical for the success of the industry.
For more information visit: http://www.rncos.com/Report/IM557.htm
Some of our Related Reports are as follows:Â
Related Releases are as follows:
- Novel Parkinson Disease Drugs Aid in Reducing “Off” Time in Patients
- Nanotechnology Mediated Targeted Drug Delivery for Cancer Treatment: Gaining Momentum
- Stem Cell Therapy – A Breakthrough in Parkinson’s Disease Treatment
- Lentiviral Vectors: Emerging as a Promising Tool for T-Cell Immunotherapy
- Nanosized Drug Delivery Systems Revolutionizing Entire Drug Therapy Strategy
Media Citation
- testtest
19 Jan, 2024 - Yourstory.com News @ Foodtech startup Swiggy launches Health Hub in Chennai
23 Mar, 2021 - Yourstory.com News @ Zomato forays into dietary supplements, makes its own 'made in India' brand
16 Mar, 2021 - View more
get in touch
Copyright © 2014, RNCOS, 2002-2014
About Us
Terms & Policy
Contact